DOVRTĚLOVÁ, Gabriela, Ondřej ZENDULKA, Kristýna NOSKOVÁ, Jan JUŘICA, Ondřej PEŠ, Jan DUŠEK, Alejandro CARAZO, Iveta ZAPLETALOVÁ, Nataša HLAVÁČOVÁ and Petr PÁVEK. Effect of Endocannabinoid Oleamide on Rat and Human Liver Cytochrome P450 Enzymes in In Vitro and In Vivo Models. Drug Metabolism and Disposition. Bethesda: AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS, 2018, vol. 46, No 6, p. 913-923. ISSN 0090-9556. Available from: https://dx.doi.org/10.1124/dmd.117.079582.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Effect of Endocannabinoid Oleamide on Rat and Human Liver Cytochrome P450 Enzymes in In Vitro and In Vivo Models
Authors DOVRTĚLOVÁ, Gabriela (203 Czech Republic, belonging to the institution), Ondřej ZENDULKA (203 Czech Republic, guarantor, belonging to the institution), Kristýna NOSKOVÁ (203 Czech Republic, belonging to the institution), Jan JUŘICA (203 Czech Republic, belonging to the institution), Ondřej PEŠ (203 Czech Republic, belonging to the institution), Jan DUŠEK (203 Czech Republic), Alejandro CARAZO (724 Spain), Iveta ZAPLETALOVÁ (203 Czech Republic), Nataša HLAVÁČOVÁ (703 Slovakia) and Petr PÁVEK (203 Czech Republic).
Edition Drug Metabolism and Disposition, Bethesda, AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS, 2018, 0090-9556.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30104 Pharmacology and pharmacy
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 3.354
RIV identification code RIV/00216224:14110/18:00100907
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1124/dmd.117.079582
UT WoS 000439228300016
Keywords in English cytochrome P450; enzyme inhibitors; liver; hepatic; pharmacokinetics
Tags 14110512, 14110516, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 27/1/2021 13:04.
Abstract
The endocannabinoid system is important for many physiological and pathological processes, but its role in the regulation of liver cytochromes P450 (CYPs) is still unknown.We studied the influence of the endocannabinoid oleamide on rat and human liver CYPs. Oleamide was administered i.p. to rats at doses of 0.1, 1 and 10 mg/kg/day for 7 days. The content and activity of key CYPs was evaluated in rat liver microsomes. Moreover, its interactions with nuclear receptors regulating CYP genes and serum levels of their ligands (prolactin, corticosterone, and free triiodothyronine) were tested in vitro CYP inhibition assays. Decreased protein levels and metabolic activities of CYP1A2, CYP2B, and CYP2C11 along with a drop in metabolic activity of CYP2D2 were observed in animals treated with oleamide (10 mg/kg/day). The activities of CYP2C6, CYP2A, and CYP3A and the levels of hormones were not altered. In vitro, oleamide exhibited a weak inhibition of rat CYP1A2, CYP2D2, and CYP2C6. The activities of rat CYP2A, CYP2B, CYP2C11, and CYP3A and human CYP1A2, CYP2B6, CYP2C9, and CYP3A4 were not altered. Oleamide did not interact with human pregnane X, constitutive androstane and aryl hydrocarbon receptors in reporter gene experiments and did not regulate their target CYP genes in primary human hepatocytes. Our results indicate that oleamide caused the downregulation of some rat liver CYPs, and hormones are not mediators of this effect. In vitro oleamide inhibits mainly rat CYP2C6 and it is neither an agonist nor antagonist of major human nuclear receptors involved in the regulation of xenobiotic metabolism.
Links
GA16-06106S, research and development projectName: Vysoce efektivní systém založený na kapilární elektroforéze pro screening inhibitorů beta-sekretázy jako terapeutického cíle pro Alzheimerovu chorobu (Acronym: Alzheimer)
Investor: Czech Science Foundation
LM2015090, research and development projectName: Český národní uzel Evropské sítě infrastruktur klinického výzkumu (Acronym: CZECRIN)
Investor: Ministry of Education, Youth and Sports of the CR
MUNI/A/0910/2017, interní kód MUName: Studium molekulární podstaty vybraných patologických stavů a onemocnění (Acronym: stumopo)
Investor: Masaryk University, Category A
MUNI/A/1132/2017, interní kód MUName: Behaviorální psychofarmakologie a farmakokinetika v preklinickém výzkumu léčiv
Investor: Masaryk University, Category A
PrintDisplayed: 20/7/2024 19:26